Partner
Souvien Therapeutics, Ltd.
Souvien Therapeutics, Ltd. is a biotechnology company focused on developing novel therapeutic agents to modulate critical epigenetic mechanisms associated with neurodegeneration.
Souvien is founded on the pioneering research of
The development plan is based on a substantial body of data implicating a critical epigenetic regulator of cellular aging in neurodegeneration. The goal is to use that knowledge, and the greatly evolving understanding of aging, to bring new drugs into human trials.
In the News
Juvenescence
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
May 28, 2019
Read More